Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
Cathepsin V
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "Cathepsin V" in MCE Product Catalog:
7
7 Publications Verification
Cat. No.: HY-W010347
CAS No.: 6027-13-0
Category:
Human Gut Microbiota Metabolites Microorganisms Anti-aging Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Inflammation/Immunology
Target:
1
1 Cited Publications
Cat. No.: HY-W653733
CAS No.: 331665-12-4
1
1 Cited Publications
Cat. No.: HY-15958
CAS No.: 1310340-58-9
Target:
Research Areas:
VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic effects .
1
1 Cited Publications
Cat. No.: HY-P78682
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CTSB; Keratolytic Winter Erythema (Oudtshoorn Skin Disease); Cathepsin B; Epididymis Secretory Sperm Binding Protein; APP Secretase; Amyloid Precursor Protein Secretase; Cathepsin B1; Cysteine Protease; APPS; RECEUP; CPSB; KWE
Cat. No.: HY-162874
CAS No.: 3035557-60-6
diABZI-V/C-DBCO is a STING agonist with an EC50 of 1.47 nM. diABZI-V/C-DBCO activates the STING pathway, induces the production of IFN-I, and stimulates the secretion of IFN-β. diABZI-V/C-DBCO serves as a substrate for cathepsin B, and releases active diABZI-amine via cathepsin B-mediated cleavage. In an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO increases serum IFN-β levels and the frequency of granzyme B + CD8 + T cells. diABZI-V/C-DBCO is applicable to research related to triple-negative breast cancer .
Cat. No.: HY-164278
CAS No.: 3035557-55-9
diABZI-V/C-Mal is a STING agonist (with a STING EC50 of 314 nM in TH1 dual reporter cells) and a Cathepsin B substrate. diABZI-V/C-Mal activates STING, thereby triggering the IRF3 signaling pathway. diABZI-V/C-Mal is cleaved by Cathepsin B to regenerate diABZI-NH2 .
Synonyms: SB-462795
Target:
Research Areas:
Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
Cat. No.: HY-W796158
CAS No.: 250584-13-5
Target:
Research Areas:
Cat. No.: HY-W010347R
CAS No.: 6027-13-0
Cat. No.: HY-P5377
CAS No.: 221055-89-6
Synonyms: Cathepsin K substrate
Target:
Research Areas:
Cat. No.: HY-15958A
Target:
Research Areas:
(S,R,R)-VBY-825 is the isomer of VBY-825 (HY-15958), and can be used as an experimental control. VBY-825 is a novel reversible inhibitor of cathepsin with high inhibition of cathepsin B, L, S and V.
Cat. No.: HY-P705678
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CTSB; Keratolytic Winter Erythema (Oudtshoorn Skin Disease); Cathepsin B; Epididymis Secretory Sperm Binding Protein; APP Secretase; Amyloid Precursor Protein Secretase; Cathepsin B1; Cysteine Protease; APPS; RECEUP; CPSB; KWE
Cat. No.: HY-10294R
CAS No.: 362505-84-8
Synonyms: SB-462795 (Standard)
Target:
Research Areas:
Relacatib (Standard) is the analytical standard of Relacatib (HY-10294). This product is intended for research and analytical applications. Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
Cat. No.: HY-P86837
Synonyms: Cathepsin L antibody; Cathepsin L 1 b antibody; Cathepsin L1 antibody; Cathepsin L1 light chain antibody; CathepsinL antibody; CATL antibody; CATL1_HUMAN antibody; cb15 antibody; CTSL antibody; Cathepsin L antibody; Cathepsin L 1 b antibody; Cathepsin L1 antibody; Cathepsin L1 light chain antibody; CathepsinL antibody; CATL antibody; CATL1_HUMAN antibody; cb15 antibody; CTSL antibody; CTSL1 antibody; ctsl1b antibody; FLJ31037 antibody; hgg1 antibody; Major excreted protein antibody; MEP antibody; MGC123162 antibody; wu:fb30g09 antibody;
Cat. No.: HY-187367
Target:
Research Areas:
WJM590 is an orally active antimalarial agent that also exhibits inhibitory activities against renin, cathepsin D, BACE1, and plasmodial aspartic proteases. WJM590 inhibits substrate and protein maturation processing mediated by key proteases of Plasmodium falciparum, arrests asexual blood-stage parasites at the late schizont stage, inhibits merozoite release, and blocks malaria parasite transmission via vectors. WJM590 exerts selective inhibitory activity against multiple Plasmodium species and drug-resistant Plasmodium falciparum strains, and reduces parasitemia in infected mice. WJM590 can be used in malaria-related research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
